Protalix Biotherapeutics Inc. buy stratec
Summary
This prediction ended on 05.11.21 with a price of €0.94. Massive losses of -81.68% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Protalix Biotherapeutics Inc. | -7.392% | -7.392% | -35.519% | -25.212% |
iShares Core DAX® | -3.935% | -2.628% | 10.013% | 11.951% |
iShares Nasdaq 100 | -3.608% | -9.283% | 20.668% | 35.711% |
iShares Nikkei 225® | -4.513% | -6.951% | 5.241% | 2.602% |
iShares S&P 500 | -2.607% | -4.402% | 20.177% | 37.820% |
Comments by stratec for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix is a Buy for investors who are patient and brave...
Protalix has the first FDA-approved plant cell expressed protein, Elelyso for Gaucher disease, and has three other drug candidates in its pipeline.
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). Phase 3 interim data for its Fabry disease franchise will be reported in 2018. PRX-102 has less antibody formation (and antibodies only stay in the body briefly).
The orphan disease market is lucrative with PRX-102 to potentially become the new standard of care.
stratec stimmt am 03.02.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 5.22€ zu.
In the thread Trading Protalix Biotherapeutics Inc.